These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 25619468)
21. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Goldstone SE; Vuocolo S Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023 [TBL] [Abstract][Full Text] [Related]
22. Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Hawkes M; Campisi P; Zafar R; Punthakee X; Dupuis A; Forte V; Ford-Jones EL Pediatr Infect Dis J; 2008 Feb; 27(2):149-54. PubMed ID: 18174855 [TBL] [Abstract][Full Text] [Related]
23. Adult-onset recurrent respiratory papillomatosis: a review of disease pathogenesis and implications for patient counseling. Taliercio S; Cespedes M; Born H; Ruiz R; Roof S; Amin MR; Branski RC JAMA Otolaryngol Head Neck Surg; 2015 Jan; 141(1):78-83. PubMed ID: 25393901 [TBL] [Abstract][Full Text] [Related]
24. [Recurrent respiratory papillomatosis: indication for HPV vaccination?]. Pawlita M; Gissmann L Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S100-2. PubMed ID: 19353471 [TBL] [Abstract][Full Text] [Related]
25. Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis. Bentley PL; Coulter MJ; Nelson BL Head Neck Pathol; 2019 Jun; 13(2):235-238. PubMed ID: 29594918 [TBL] [Abstract][Full Text] [Related]
27. Use of intralesional cidofovir in the recurrent respiratory papillomatosis: a review of the literature. Gazia F; Galletti B; Freni F; Bruno R; Sireci F; Galletti C; Meduri A; Galletti F Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):956-962. PubMed ID: 32017003 [TBL] [Abstract][Full Text] [Related]
28. Concurrent oral human papilloma virus infection in patients with recurrent respiratory papillomatosis: a preliminary study. Born H; Ruiz R; Verma A; Taliercio S; Achlatis S; Pitman M; Gandonu S; Bing R; Amin MR; Branski RC Laryngoscope; 2014 Dec; 124(12):2785-90. PubMed ID: 25059492 [TBL] [Abstract][Full Text] [Related]
29. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey. Best SR; Mohr M; Zur KB Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692 [TBL] [Abstract][Full Text] [Related]
30. Degrees of dysplasia based on viral typing in patients with cidofovir use and recurrent respiratory papillomatosis. Moore JE; Garcia A; Sanyal S; Saunders S; Portnoy JE; Hu A; Sataloff RT J Voice; 2013 Nov; 27(6):765-8. PubMed ID: 24128893 [TBL] [Abstract][Full Text] [Related]
31. Human Papillomavirus Vaccination as an Adjuvant Therapy for Recurrent Respiratory Papillomatosis: Additional Case Series. Matsuzaki H; Makiyama K; Hasegawa H; Asai R; Morita M; Oshima T J Voice; 2024 Jan; 38(1):204-209. PubMed ID: 34600799 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. Sullivan C; Curtis S; Mouzakes J Int J Pediatr Otorhinolaryngol; 2017 Feb; 93():103-106. PubMed ID: 28109479 [TBL] [Abstract][Full Text] [Related]
33. [Extragenital, disseminated infection with human papillomaviruses : Therapeutic response through vaccination with HPV]. Wiskemann L; Durani B; Hartschuh W Hautarzt; 2018 Mar; 69(3):245-248. PubMed ID: 29134256 [TBL] [Abstract][Full Text] [Related]
34. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L; J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418 [TBL] [Abstract][Full Text] [Related]
36. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Tjon Pian Gi RE; San Giorgi MR; Slagter-Menkema L; van Hemel BM; van der Laan BF; van den Heuvel ER; Dikkers FG; Schuuring EM Head Neck; 2015 Nov; 37(11):1625-32. PubMed ID: 24955561 [TBL] [Abstract][Full Text] [Related]
37. Suspected side effects to the quadrivalent human papilloma vaccine. Brinth L; Theibel AC; Pors K; Mehlsen J Dan Med J; 2015 Apr; 62(4):A5064. PubMed ID: 25872549 [TBL] [Abstract][Full Text] [Related]
38. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Geier DA; Geier MR Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199 [TBL] [Abstract][Full Text] [Related]
39. Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates. Novakovic D; Cheng AT; Baguley K; Walker P; Harrison H; Soma M; Malloy M; Brotherton JM Laryngoscope; 2016 Dec; 126(12):2827-2832. PubMed ID: 27074766 [TBL] [Abstract][Full Text] [Related]
40. The prophylactic role for the human papillomavirus quadrivalent vaccine in males. Yancey AM; Pitlick JM; Forinash AB Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]